Search results
Showing 721 to 735 of 8885 results
All NICE products on brain cancers. Includes any guidance, advice and quality standards.
All NICE products on breast cancer. Includes any guidance, advice and quality standards.
All NICE products on staffing. Includes any guidance.
All NICE products on organ and tissue transplantation. Includes any guidance, advice and quality standards.
All NICE products on pressure ulcers. Includes any guidance, advice and quality standards.
All NICE products on urinary tract infection. Includes any guidance, advice and quality standards.
All NICE products on lower urinary tract symptoms. Includes any guidance, advice and quality standards.
All NICE products on parkinson's disease, tremor and dystonia. Includes any guidance, advice and quality standards.
All NICE products on mesothelioma. Includes any guidance.
All NICE products on vulnerable groups. Includes any guidance and quality standards.
All NICE products on people with physical disabilities. Includes any guidance.
All NICE products on schools and other educational settings. Includes any guidance and quality standards.
All NICE products on community settings. Includes any guidance and quality standards.
This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.
View quality statements for QS180Show all sections
Sections for QS180
- Quality statements
- Quality statement 1: Referral – chronic open angle glaucoma and related conditions
- Quality statement 2: Referral for cataract surgery
- Quality statement 3: Treatment – late age-related macular degeneration (wet active)
- Quality statement 4: Monitoring late age-related macular degeneration (wet active)
- Quality statement 5: Reassessment – chronic open angle glaucoma or related conditions
- Quality statement 6: Certificate of vision impairment
- Update information
In development Reference number: GID-TA11232 Expected publication date: 29 April 2026